Serina Therapeutics Announces Publication of SER-214 Clinical Trial Results in Movement Disorders Journal

Huntsville, AL, April 8th 2020

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary drug delivery technology platform, announced today that the clinical trial results of SER-214 were published in the Journal of Movement Disorders.

“We are excited to announce that the results of our lead clinical candidate SER-214, a once-weekly subcutaneous treatment for Parkinson’s disease, have been published in Movement Disorders – one of the top tier journals in neuroscience,” stated Dr. Moreadith.

The results of the clinical trial showed SER-214 was safe, very well-tolerated and indicated that the release of rotigotine from the polymer may provide efficacy – even in stably treated patients. Movement Disorders is one of the top journals in neuroscience, with an impact factor of 8.3. An impact factor of 8.3 places Movement Disorders at 11 of 197 peer-reviewed publications in the neurosciences. A copy of the article is available in the publication archives on the Serina website.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that is developing novel polymer therapeutics based on its proprietary polyoxazoline (POZ™) technology. The founders and managers of Serina were formerly the principals of Shearwater Polymers which enabled fourteen approved polyethylene glycol (PEG) products for various pharmaceutical partners. POZ™ technology provides strong differential characteristics that may demonstrate improved safety, tolerability and clinical benefits versus PEG and other polymer-based technologies.

In addition to a growing CNS-focused pipeline of proprietary programs in pain, Parkinson’s disease and epilepsy Serina seeks partnership opportunities with pharmaceutical companies to further unlock the promise of the POZ™ platform.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com.